VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 96 filers reported holding VERVE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 2.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $68,959,525 | -28.6% | 5,200,567 | +1.0% | 0.53% | -17.4% |
| Q2 2023 | $96,578,455 | +49.4% | 5,150,851 | +14.9% | 0.64% | +43.9% |
| Q1 2023 | $64,631,752 | -23.5% | 4,482,091 | +2.7% | 0.44% | -39.3% |
| Q4 2022 | $84,478,811 | -27.5% | 4,365,830 | +28.6% | 0.73% | -10.0% |
| Q3 2022 | $116,579,000 | +278.0% | 3,393,859 | +66.8% | 0.81% | +346.7% |
| Q2 2022 | $30,837,000 | -19.9% | 2,034,124 | +20.6% | 0.18% | +13.0% |
| Q1 2022 | $38,496,000 | -25.4% | 1,686,945 | +20.5% | 0.16% | +3.2% |
| Q4 2021 | $51,601,000 | -13.4% | 1,399,545 | +10.4% | 0.16% | +9.1% |
| Q3 2021 | $59,582,000 | +80.3% | 1,267,705 | +131.2% | 0.14% | +134.4% |
| Q2 2021 | $33,040,000 | – | 548,389 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |